Latest Medical Devices News

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Adherium Limited has raised A$0.35 million through an institutional placement, supplementing its recent entitlement offer to strengthen its financial position and support growth initiatives.

Resmed Inc. reported a robust 10% revenue increase and a 19% rise in operating profit for fiscal 2025, alongside a 13% dividend hike, driven by strong demand for sleep and breathing health devices and growth in digital health software.

Cardiex reported strong growth in its Pulse arterial health monitor sales during Q4 FY25, surpassing A$0.7 million for the year and advancing its transition to subscription-based digital health services.

Cardiex Limited reported a $3 million cash outflow in Q4 2025 but is banking on cost reductions and new product sales to improve its financial footing. The company also secured $6.5 million through a capital raise to bolster its runway.

Adherium Limited reports a robust 30% increase in US remote patient monitoring users and closes a $4.5 million capital raise, positioning itself for accelerated growth under new leadership.

Resonance Health reports a solid quarter with key clinical trial milestones, expansion of trial sites, and multi-year Software-as-a-Medical Device contracts, underpinning a positive cashflow outlook.

Control Bionics capped a record FY25 with 15% revenue growth, driven by US market gains and expanding NeuroNode and NeuroStrip technologies. The company also achieved a US profitability milestone and is close to finalizing key distribution partnerships.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

PainChek Limited has secured a A$7.5 million placement to fuel its international expansion, with US FDA clearance for its adult pain assessment app expected imminently. The company reports strong license growth and a 26% revenue increase year-on-year.